Kilitch Drugs: Monitoring Agency Report for Right Issue Proceeds

Kilitch Drugs India Ltd has submitted its Monitoring Agency Report for the quarter ended June 30, 2026, concerning its Right Issue of equity shares amounting to ₹49.92 crore. The report, issued by Infomerics Valuation and Rating Limited, confirms no deviation from the objects for which the issue proceeds were earmarked. This disclosure aligns with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. The company will also host this report on its website.